Suven Pharmaceuticals Limited (SUVENPHAR) - Net Assets
Based on the latest financial reports, Suven Pharmaceuticals Limited (SUVENPHAR) has net assets worth Rs18.41 Billion INR (≈ $199.06 Million USD) as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs30.32 Billion ≈ $327.87 Million USD) and total liabilities (Rs11.91 Billion ≈ $128.81 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Suven Pharmaceuticals Limited's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs18.41 Billion |
| % of Total Assets | 60.71% |
| Annual Growth Rate | 20.86% |
| 5-Year Change | 55.88% |
| 10-Year Change | N/A |
| Growth Volatility | 17.98 |
Suven Pharmaceuticals Limited - Net Assets Trend (2019–2025)
This chart illustrates how Suven Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. Also explore Suven Pharmaceuticals Limited asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Suven Pharmaceuticals Limited (2019–2025)
The table below shows the annual net assets of Suven Pharmaceuticals Limited from 2019 to 2025. For live valuation and market cap data, see Suven Pharmaceuticals Limited market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs18.41 Billion ≈ $199.06 Million |
-10.24% |
| 2024-03-31 | Rs20.51 Billion ≈ $221.77 Million |
+18.18% |
| 2023-03-31 | Rs17.35 Billion ≈ $187.65 Million |
+13.62% |
| 2022-03-31 | Rs15.27 Billion ≈ $165.16 Million |
+29.33% |
| 2021-03-31 | Rs11.81 Billion ≈ $127.70 Million |
+39.78% |
| 2020-03-31 | Rs8.45 Billion ≈ $91.36 Million |
+43.11% |
| 2019-03-31 | Rs5.90 Billion ≈ $63.84 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Suven Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rs254.60 Million | 1.50% |
| Other Components | Rs16.71 Billion | 98.50% |
| Total Equity | Rs16.97 Billion | 100.00% |
Suven Pharmaceuticals Limited Competitors by Market Cap
The table below lists competitors of Suven Pharmaceuticals Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KONINKLIJKE VOP.UNSP.ADR
F:VPK
|
$4.40 Billion |
|
Brown-Forman Corporation
NYSE:BF-A
|
$4.41 Billion |
|
Grupo Aeroportuario del Centro Norte SAB de CV
NASDAQ:OMAB
|
$4.41 Billion |
|
Georg Fischer AG
SW:GF
|
$4.42 Billion |
|
RadNet Inc
NASDAQ:RDNT
|
$4.40 Billion |
|
MDU Resources Group Inc
NYSE:MDU
|
$4.40 Billion |
|
Clear Secure Inc
NYSE:YOU
|
$4.40 Billion |
|
Charoen Pokphand Foods Public Company Limited
F:NVAV
|
$4.39 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Suven Pharmaceuticals Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 20,506,635,000 to 16,965,800,000, a change of -3,540,835,000 (-17.3%).
- Net income of 2,647,700,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 1,505,152,000.
- Other factors decreased equity by 4,683,383,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs2.65 Billion | +15.61% |
| Other Comprehensive Income | Rs-1.51 Billion | -8.87% |
| Other Changes | Rs-4.68 Billion | -27.6% |
| Total Change | Rs- | -17.27% |
Book Value vs Market Value Analysis
This analysis compares Suven Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 15.89x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 45.88x to 15.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-03-31 | Rs23.19 | Rs1063.80 | x |
| 2020-03-31 | Rs33.18 | Rs1063.80 | x |
| 2021-03-31 | Rs46.39 | Rs1063.80 | x |
| 2022-03-31 | Rs59.99 | Rs1063.80 | x |
| 2023-03-31 | Rs68.16 | Rs1063.80 | x |
| 2024-03-31 | Rs80.56 | Rs1063.80 | x |
| 2025-03-31 | Rs66.96 | Rs1063.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Suven Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.61%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 22.11%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.79x
- Recent ROE (15.61%) is below the historical average (24.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 18.51% | 29.84% | 0.47x | 1.33x | Rs502.45 Million |
| 2020 | 37.53% | 39.28% | 0.69x | 1.39x | Rs2.33 Billion |
| 2021 | 30.69% | 36.98% | 0.66x | 1.25x | Rs2.44 Billion |
| 2022 | 29.72% | 35.18% | 0.70x | 1.20x | Rs3.01 Billion |
| 2023 | 23.70% | 30.69% | 0.68x | 1.13x | Rs2.38 Billion |
| 2024 | 14.64% | 28.56% | 0.47x | 1.10x | Rs952.14 Million |
| 2025 | 15.61% | 22.11% | 0.40x | 1.79x | Rs951.12 Million |
Industry Comparison
This section compares Suven Pharmaceuticals Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $23,713,303,062
- Average return on equity (ROE) among peers: 8.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Suven Pharmaceuticals Limited (SUVENPHAR) | Rs18.41 Billion | 18.51% | 0.65x | $4.40 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $988.60 Million | 6.59% | 1.36x | $27.93 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $6.52 Billion | 21.67% | 1.42x | $371.43 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $19.90 Billion | 13.69% | 0.46x | $725.68 Million |
| Abbott India Limited (ABBOTINDIA) | $36.99 Billion | 32.48% | 0.40x | $5.85 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $1.16 Billion | 12.69% | 1.32x | $3.81 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $6.25 Billion | -40.39% | 3.91x | $906.19 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $6.98 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.46 Billion | 16.82% | 0.29x | $178.52 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $51.90 Billion | 11.24% | 0.50x | $1.60 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $23.50 Billion | -5.26% | 1.65x | $8.73 Billion |
About Suven Pharmaceuticals Limited
Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research servic… Read more